Trials / NCT07796646
Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Not yet recruiting Phase 2 RNA / antisense
- Sponsor
- Laboratoires Thea
- Treatment
- No intervention, will not receive any active study intervention; Intravitreal Injection of Ultevursen
- Gene
- USH2A
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Ages
- 8 Years to no upper limit
- Enrollment
- 81 participants
- Started
- 2026-10-05
- Main results expected
- 2030-02-28
- Results posted
- Not yet
- Record last updated
- 2026-09-01
What the study is testing
The purpose of this Phase 2 Open-label study is to evaluate the long-term safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in participants with Retinitis Pigmentosa due to mutations in exon 13 of the USH2A gene. This is a multicenter study which will enroll approximately 81 participants, however, the exact number enrolled will depend on the final number completing the 24-month LUNA trial and are eligible and willing to enroll in CAPELLA.
Where it runs
No sites listed yet.